In the OT‐I transfer model, which is widely recognized as a traditional framework for investigating the functions of tumor‐specific CD8+ T cells,[83] we found that tumor‐specific TCM‐like cells in the TdLN expressed CD44, CD62L, CD127, and TCF‐1, while maintaining low expression of PD‐1, a phenotype consistent with the recently identified TdLN‐TTSM cell.[59] The proportion of tumor‐specific TCM‐like cells in the TdLN was significantly increased after combined treatment, suggesting that the combined treatment promotes the differentiation of TTSM cells. The gene discussed is SELL; the disease is neoplasm.